Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Lonapegsomatropin
Therapeutic Area : Endocrinology
Study Phase : Approved
Sponsor : Ascendis Pharma
Deal Size : Undisclosed
Deal Type : Agreement
Specialised Therapeutics Signs Agreement for Three Endocrinology Therapies
Details : Specialised Therapeutics will commercialize Ascendis' injectable pediatric growth hormone SKYTROFA, hypoparathyroidism treatment YORVIPATH, and investigational therapy TransCon CNP.
Brand Name : Skytrofa
Molecule Type : Large molecule
Upfront Cash : Undisclosed
January 07, 2024
Lead Product(s) : Lonapegsomatropin
Therapeutic Area : Endocrinology
Highest Development Status : Approved
Sponsor : Ascendis Pharma
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Oregovomab,Carboplatin,Paclitaxel
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : CanariaBio
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the terms of the arrangement, ST will be responsible for all commercial, medical, regulatory and distribution activities for oregovomab in its key territories of Australia, New Zealand, Singapore, Thailand, Vietnam, Brunei and Malaysia.
Brand Name : MAb-B43.13
Molecule Type : Large molecule
Upfront Cash : Undisclosed
October 12, 2023
Lead Product(s) : Oregovomab,Carboplatin,Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : CanariaBio
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Treeway Licensing Deal with Specialised Therapeutics
Details : Under the licensing agreement, ST will be responsible for all marketing, regulatory and distribution activities of TW001, a unique oral formulation of edaravone which works by reducing the oxidative damage associated with neuron death in ALS, in Australi...
Brand Name : TW001
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 28, 2023
Lead Product(s) : Tafasitamab,Lenalidomide
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lymphoma Therapy Now Approved for Australian Patients with Diffuse Large B-Cell Lymphoma
Details : Monjuvi® and Minjuvi® (tafasitamab) is a humanized Fc-modified CD19 targeting immunotherapy used in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.
Brand Name : Minjuvi
Molecule Type : Large molecule
Upfront Cash : Not Applicable
June 28, 2023
Lead Product(s) : Tafasitamab,Lenalidomide
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Trabectedin
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Global Sarcoma Therapy Now Approved for New Zealand Patients
Details : Yondelis (trabectedin) binds guanine residues in the minor groove of DNA, forming adducts and resulting in a bending of the DNA helix triggering a cascade of events like DNA repair pathways, resulting in perturbation of the cell cycle and eventual cell d...
Brand Name : Yondelis
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 17, 2023
Lead Product(s) : Trabectedin
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ripretinib
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
New Therapy to Treat Rare Gastrointestinal Stromal Tumour Approved for New Zealand Patients
Details : Qinlock (ripretinib) is a switch-control tyrosine kinase inhibitor that was engineered to broadly inhibit KIT and PDGFRA mutated kinases, involved in GIST, by using a dual mechanism of action that regulates the kinase switch pocket and activation loop.
Brand Name : Qinlock
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 20, 2023
Lead Product(s) : Ripretinib
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Pemigatinib
Therapeutic Area : Oncology
Study Phase : Approved
Recipient : Incyte Corporation
Deal Size : Not Applicable
Deal Type : Not Applicable
New Treatment for Rare Cancer Cholangiocarcinoma Approved in Australia
Details : PEMAZYRE (pemigatinib) a FGFR inhibitor, is used for the treatment of adult patients with metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that has progressed after at least one prior line of system...
Brand Name : Pemazyre
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 15, 2022
Lead Product(s) : Pemigatinib
Therapeutic Area : Oncology
Highest Development Status : Approved
Recipient : Incyte Corporation
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Tafasitamab,Lenalidomide
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Incyte Corporation
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the terms of the agreement, Incyte will be responsible for the development, manufacture and supply of both products tafasitamab (sold as Monjuvi) and pemigatinib (Pemazyre) and ST will be responsible for regulatory, distribution and local marketing...
Brand Name : Minjuvi
Molecule Type : Large molecule
Upfront Cash : Undisclosed
October 22, 2021
Lead Product(s) : Tafasitamab,Lenalidomide
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Incyte Corporation
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Lurbinectedin
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : PharmaMar
Deal Size : Not Applicable
Deal Type : Not Applicable
New Therapy to Treat Advanced Small Cell Lung Cancer ZEPZELCA® (lurbinectedin) Approved in Singapore
Details : ZEPZELCA® (lurbinectedin) is an alkylating drug that binds guanine residues within DNA. This triggers cascade of events that can affect activity of DNA binding proteins, including some transcription factors to treat 2L metastatic small cell lung cancer.
Brand Name : Zepzelca
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 22, 2021
Lead Product(s) : Lurbinectedin
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : PharmaMar
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Lurbinectedin
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : PharmaMar
Deal Size : Not Applicable
Deal Type : Not Applicable
New Therapy to Treat Advanced Small Cell Lung Cancer Approved for Australian Patients
Details : ZEPZELCA® (lurbinectedin) is the first new therapy approved to treat second-line metastatic SCLC in Australia in more than 20 years. ZEPZELCA approval granted under a provisional regulatory pathway.
Brand Name : Zepzelca
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 14, 2021
Lead Product(s) : Lurbinectedin
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : PharmaMar
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?